Mesenchymal stem cells as therapeutic target of biophysical stimulation for the treatment of musculoskeletal disorders

Marco Viganò 1,2, Valerio Sansone 1,3, Maria Cristina d’Agostino 4, Pietro Romeo 1, Carlotta Perucca Orfei 1,5 and Laura de Girolamo 1*

Abstract

Background: Musculoskeletal disorders are regarded as a major cause of worldwide morbidity and disability, and they result in huge costs for national health care systems. Traditional therapies frequently turned out to be poorly effective in treating bone, cartilage, and tendon disorders or joint degeneration. As a consequence, the development of novel biological therapies that can treat more effectively these conditions should be the highest priority in regenerative medicine.

Main body of the abstract: Mesenchymal stem cells (MSCs) represent one of the most promising tools in musculoskeletal tissue regenerative medicine, thanks to their proliferation and differentiation potential and their immunomodulatory and trophic ability. Indeed, MSC-based approaches have been proposed for the treatment of almost all orthopedic conditions, starting from different cell sources, alone or in combination with scaffolds and growth factors, and in one-step or two-step procedures. While all these approaches would require cell harvesting and transplantation, the possibility to stimulate the endogenous MSCs to enhance their tissue homeostasis activity represents a less-invasive and cost-effective therapeutic strategy. Nowadays, the role of tissue-specific resident stem cells as possible therapeutic target in degenerative pathologies is understudied. Biophysical stimulations, and in particular extracorporeal shock waves treatment and pulsed electromagnetic fields, are able to induce proliferation and support differentiation of MSCs from different origins and affect their paracrine production of growth factors and cytokines.

Short conclusions: The present review reports the attempts to exploit the resident stem cell potential in musculoskeletal pathologies, highlighting the role of MSCs as therapeutic target of currently applied biophysical treatments.

Keywords: Mesenchymal stem cells, Pericytes, Electromagnetic fields, PEMF, Shock waves, ESWT
at least toward osteoblasts, adipocytes, and chondroblasts cell lines [2]. In addition to bone marrow, which is the most traditional source, MSCs have been isolated from almost all body compartments [3], including tendons [4], periosteum [5], trabecular bone [6], adipose tissue [7], synovial membrane [8], and muscle [9]. This multilocalization of MSCs relies on their origin; indeed, it is now well established that MSCs, or their precursors, lie in perivascular locations in all the vascularized tissues [10]. Accurate studies have demonstrated that microvascular pericytes [10] and adventitial cells [11], both freshly isolated or expanded in culture, are indistinguishable from conventional MSCs; hence, the terms perivascular stem cells or pericytes (PSCs) have been applied to these cells as well.

In addition to their ability to differentiate and to participate directly to the regeneration process, MSCs present further therapeutic functions in response to injury. Indeed, in response to particular conditions, MSCs are able to release a plethora of cytokines and growth factors with immunomodulatory and trophic effect on the pathological tissues [1]. Immunomodulatory activity is mediated by direct cell-cell contact and through secreted bioactive molecules involving dendritic cells, B and T cells [12], whereas trophic effects of MSCs are based on the secretion of molecules that inhibit apoptosis and fibrosis, and the stimulation of angiogenesis through the secretion of vascular endothelial growth factor (VEGF) [13]. For all these reasons they have been recently called "drug-stores" [1].

All these features support the application of MSCs to a wide range of pathologies characterized by inflammation and degeneration, either alone [14] or in combination with scaffolds [15], the latter especially when used in tissue engineering applications to obtain artificial biologic substitutes.

Mesenchymal stem cells: a multimodal tool to treat musculoskeletal diseases

The therapeutic potential of MSCs have been largely investigated in in vitro and preclinical settings, as well as in many studies at clinical level, for their ability to improve healing from orthopedic conditions such as chondral lesion [16], osteoarthritis [17], tendinopathy [18], intervertebral disk disease [19], and bone non-union/delayed unions [20]. MSCs have been used either expanded [21] or as concentrated progenitor pools [22], both with satisfactory results.

Even if further studies are needed to confirm their utility and to standardize applications, the results of the use of MSCs in orthopedic conditions are very promising and many studies are nowadays ongoing [17].

On the contrary, the possibility to stimulate resident MSCs in order to improve physiological tissue healing is relatively innovative, and very few studies are reported in literature on this topic so far. This idea is supported by different studies conducted in pathological conditions demonstrating that MSCs, exposed to damage associated molecular pattern (DAMP) or pathogen-associated molecular pattern (PAMP), could react by reverting the production of pro-inflammatory to anti-inflammatory molecules [23, 24] and by inducing the switch from pro-inflammatory M1 macrophages maturation to the anti-inflammatory M2 phenotype [25]. These observations open the field to the hypothesis that an enhancement of MSCs potential would benefit the progress of many orthopedic conditions. Their plasticity and ability to respond to external stimuli, both physical and chemical, make MSCs a very good target for different treatments intended to improve tissue regeneration.

The purpose of this work is to review the attempts to exploit the resident stem cell potential in musculoskeletal-related pathologies, in order to highlight their function as therapeutic target. In particular, we will focus on biophysical stimulation, such as shock waves and pulsed electromagnetic fields, since they are already applied in clinical practice, and the recent advancement in the knowledge about their mechanism of action supports the hypothesis that they would be effective in the stimulation of endogenous MSCs action (Table 1).

Pulsed electromagnetic field

Pulsed electromagnetic fields (PEMFs) are a class of electromagnetic stimuli characterized by low frequency (1 to 80 Hz) and intensity ranging between 50 μT to 50 mT [26]. They were first FDA approved for the treatment of bone non-unions and delayed unions in the 1980s, and, since then, the growing interest in their mechanisms and abilities lead to a great number of scientific investigations. Indeed, the in vitro results confirmed their effectiveness in stimulating osteoblast and inhibiting osteoclasts activity [27, 28]. The mechanism underlying the effect of PEMFs on the biological tissue is still under debate, but many hypothesis and evidences were described. Patterson and colleagues reported the activation of phosphatidylinositol-3-kinase (PI3K) and mTOR (mammalian target of rapamycin) pathway, leading to the transcription of growth factors of the TGFβ family such as BMP-4 [29]. Intracellular calcium (Ca²⁺) concentration was also addressed as effector of PEMFs biological activity, in correlation with plasma membrane potential and currents [30–37]. Moreover, PEMFs are able to induce increase in the expression of adenosin A₂A receptors and integrinβ, influencing the related intracellular pathways with roles in anti-inflammatory and differentiation processes [38, 39] (Fig. 1).

The application of PEMFs to mesenchymal stem cells of different origins demonstrated their ability in the modulation of cell cycle and enhancement of
differentiation. MSCs isolated from human bone marrow-derived (hBMSCs) were the most extensively adopted cells for this kind of experiments, and most of the studies reported an increased cell proliferation after PEMFs stimulation [40–43], as well as an increase of early stage markers of osteoblastic differentiation. In particular, many studies used PEMFs as adjuvant element, together with osteoinductive medium. In this experimental settings, increase in alkaline phosphatase (ALP) production, collagen type I and Runt-related transcription factor 2 (RUNX2) expression, and release of growth factors of the TGFβ family, such as BMP-2, were reported [41, 42, 44, 45]. On the other hand, their influence on the mineralization phase of osteogenic

| MSCs origin     | PEMF                               | ESWT                               |
|-----------------|------------------------------------|------------------------------------|
| Bone marrow     | Increased proliferation [40–43]    | Increased proliferation [63]       |
|                 | Enhanced osteogenic [41, 42, 44, 45] and chondrogenic [51] differentiation | Enhanced osteogenic differentiation [61–63] |
|                 | Reduced production of inflammatory mediators [27] | —                                   |
| Adipose tissue  | Increased proliferation [52]       | Enhanced osteogenic differentiation [71, 72] and adipogenic [72] differentiation |
|                 | Enhanced chondrogenic [53] differentiation | Increased migratory ability [70]    |
| Tendon tissue   | Increased expression of tissue specific markers [56] | Increased expression of tissue specific markers [68, 69] |
|                 | Increased production of trophic and anti-inflammatory mediators [56, 57] | Increased production of trophic and anti-inflammatory mediators [69] |
| Umbilical cord  | Enhanced chondrogenic [54] differentiation | —                                   |
| Endothelial tissue | Increased proliferation [64] | Enhanced migration and homing to lesion sites [64, 65] |

**Table 1** In vitro effects of PEMF and SW on MSCs from different origins

---

**Fig. 1** Possible molecular pathways involved in the biological response to PEMFs and ESWT stimulations. Biophysical stimulations could act through ERK and mTOR pathways to enhance cell proliferation and differentiation and to modulate the inflammatory response. TRK tyrosine kinase receptor, PI3K phosphatidylinositol 3-kinases, PKB protein kinase B (also known as AKT), mTOR mechanistic target of rapamycin, NFκB nuclear factor kappa-light-chain-enhancer of activated B cells, AC adenylyl cyclase, cAMP cyclic adenosine monophosphate, PKA protein kinase A, CREB cAMP response element-binding protein, PKC protein kinase C, Rac/Ras small GTPase of the Ras superfamily, Raf serine/threonine-specific protein kinases, MEK mitogen-activated protein kinase kinase, and ERK extracellular signal-regulated kinases.


**Extracorporeal shock wave therapy**

Since its original applications as urological lithotripsy, extracorporeal shock wave therapy (ESWT) has been applied in the musculoskeletal field as orthotripsy (mainly tendinopathies and bone regenerative disorders) and regenerative medicine as well [58, 59].

The mechanisms of action of ESWT, when applied in non-urological indications, are not related to the direct mechanical effect but to the different pathways of biological reactions that derive from those acoustic stimulations, through the so-called “mechanotransduction” mechanism. Therefore, the “mechanical model” of urological lithotripsy has been substituted by a “biological” one, also supported by the current knowledge in mechanobiology, an emerging multidisciplinary field of science that investigates how physical forces and changes in cell/tissue mechanics can influence the tissue development, physiology and diseases. Although some details are still under investigation, it is known that ESWT are able to relieve pain, reduce inflammation, and induce neoangiogenesis and stem cell activities, thus improving tissue regeneration and healing [58, 60].

Indeed, early researches on this topic showed that ESWT affected, according to the amount of energy and the number of pulses, the growth ratio of bone marrow osteoprogenitor cells, forming colony-forming unit-osteoprogenitors (CFU-O) and bone nodules related to the induction of TGFβ1 molecule [61].

Subsequent experimental results revealed that these effects included the regulation of submembrane redox reactions elicited by early O2 production for tyrosine kinase-mediated ERK activation, resulting in phosphorylation of CBFA1 (core-binding factor alpha1), the transcription factor for osteoblastic differentiation, and osteogenesis (Fig. 1). The evidence that shock waves triggered the growth and maturation of osteoprogenitor cells through the pathway of mechanotransduction, prefigured following models for ex vivo extension of the mesenchymal stem cells [62]. Moreover, in a more recent work, human BMSCs exposed to shock waves showed increased proliferation and migration capacity [63].

Nevertheless, the interest on the use of ESWT in regenerative medicine arose from the studies of their application in ischemic lesions, where, besides the angiogenic and anti-inflammatory effect, emerged the hypothesis of an action addressed to the proliferation, recruitment, migration, and homing of progenitors cells in the sites of lesion [64, 65]. In fact, reversible modification of the cytoskeleton was observed in ESWT-treated cells, whose final effect, through nuclear transcription activation, is a series of specific biochemical pathways, related to local tissue turnover [66].
Indeed, already in 2005, it was demonstrated that pretreatment of hematopoietic stem cells with high energy shock waves significantly improved early progenitor cell expansion, after short-term suspension culture, prefiguring a new way to manipulate these cell populations [67].

In this perspective, MSCs, as a main target during regenerative pathways, could play a key role in orchestrating all the processes activated by shock waves [58].

Recently, basic science about shock waves was enriched of articles, describing their “regenerative effect” in many different tissues, other than the bone.

In order to elucidate the ESW-mediated clinical benefits, Leone et al., by studying TSPCs explanted from five healthy semitendinosus and five ruptured Achilles tendons found that the clonogenic potential was maintained only in cells derived from healthy donors. Moreover, ESW application significantly accelerated hTSPCs differentiation, thus suggesting that the clinical benefits of ESWT may be ascribed to increased efficiency of tendon repair after injury [68]. Indeed, these observations were confirmed in a different in vitro setting, where, TSPCs treated with ESW showed increased proliferation, expression of tendon specific markers (scleraxis and collagen type I) and production of growth factors (VEGF, TGFβ) and cytokines (IL-10), consistently with the instauration of a regenerative and anti-inflammatory microenvironment [69]. Very recently, Rinella and co-authors were able to demonstrate how ESWT would inhibit the development of a myofibroblast phenotype in human ASCs. Functionally, stem cells acquire a more fibroblast-like profile characterized by a low contractility and a high migratory ability, related to a reduced expression of integrin alpha 11, a major collagen receptor in fibroblastic cells, involved in myofibroblast differentiation. In other words, this in vitro study shows that ESW can control stem cell differentiation toward myofibroblasts and, consequently, sustain their use as a therapeutic approach in reducing the risk of skin and tissue fibrosis [70]. Other authors showed that ESWT enhances ASCs production of osteogenic markers, such as RUNX2, ALP, and mineralized matrix, but, at the same time, they could increase the production of reactive oxygen species (ROS) [71].

Very interestingly, Schuh et al., showed that human and rat ASCs respond strongly to repetitive shock wave treatments in vitro, resulting in maintenance and significant increase of mesenchymal markers (CD73, CD90, CD105), differentiation capacity toward the osteogenic and adipogenic lineage, as well as toward Schwann-cell like cells even after extended time in vitro. In their study, Schuh et al. concluded that ESWT might be a promising tool to improve ASCs quality for cell therapy in various tissue engineering and regenerative medicine applications [72].

From a general point of view, the preconditioning of MSCs by ESW appears to improve their therapeutic performance without issues about the extensive manipulation that characterizes others approaches, such as genetic manipulations [63].

Conclusions

Recently, the development of stem cell-based therapies has been quickly spreading in numerous disease areas, including musculoskeletal disorders. Whether taken from the bone marrow or adipose tissue or umbilical cord, even though they can be isolated from almost all body compartments, the mesenchymal stem cells seem to show a remarkable potential for their direct use in musculoskeletal tissues repair.

In vivo observations laid the ground for the hypothesis that mechanical factors could play a major role in regulating the development and repair of the musculoskeletal tissues. Undoubtedly, these studies have greatly improved our knowledge about MSCs response to specific stimuli and the isolation of any single variables has facilitated the discovery of several mechanotransductive mechanisms. However, the in vivo environment is definitely much more complex. Cells are exposed to several intrinsic and extrinsic mechanical cues simultaneously and to the interaction between the biophysical and biochemical environment. Beside their well-known effectiveness on the musculoskeletal tissues, the idea of a direct stimulation of the resident MSCs by shock waves and pulsed electromagnetic fields has been a recent and intriguing hypothesis. Preliminary experimental data seem to confirm that these stimuli are able to enhance MSCs homeostatic activity and, thus, their role in preventing and counteracting musculoskeletal degenerative processes.

Tissue engineering could be another key application of mechanically treated MSCs, even though there are still many technical challenges associated with isolating, expanding, differentiating, and preconditioning MSCs for subsequent implantation into the degenerate joints and tissues. Moreover, the MSCs could be exposed to abnormal physical loads in anatomical structures that have already been biomechanically compromised. Another aspect that requires a deeper knowledge is ascertaining if the in vitro cultivated cells need predifferentiation or a sort of preconditioning prior to implantation into the damaged tissues, with the aim to enhance cell survival and matrix formation. Mechanical stimulation could be a low-cost, useful tool in this respect. Nevertheless, adequate requisite and design ofMSCs cell-supporting biomaterials that will resist the enzyme-rich, mechanically load
microenvironments of the degenerated musculoskeletal tissues also remain to be better clarified.

In summary, MSC-based therapies could offer a remarkable potential to change dramatically the treatment of cartilage defects, tendon degeneration, and several other musculoskeletal disorders. The advances discussed in this review highlight the progress being made toward clinical translation of such therapeutic approaches and which might be further enhanced by the aid of mechanotransduction. However, a number of technical problems and conceptual challenges still need to be addressed as research proceeds.

Abbreviations
AECs: Amniotic epithelial cells; ALP: Alkaline phosphatase; ASCs: Adipose-derived stem cells; BMSCs: Bone marrow-derived mesenchymal stem/stromal cells; BMP-2: Bone morphogenetic protein 2; BMP-4: Bone morphogenetic protein 4; CBFA1: Core-binding factor alpha1; CD: Cluster of differentiation; CFU-O: Colony-forming unit-osteoprogenitors; DAMP: Damage associated molecular pattern; ESWT: Extracorporeal shock wave treatment; IL-10: Interleukine 10; IL-1β: Interleukine 1 beta; MSCs: Mesenchymal stem/stromal cells; mTOR: Mammalian target of rapamycin; PAMPH: Pathogen associated molecular pattern; PEMFs: Pulsed electromagnetic fields; PSCs: Perivasular stem cells; ROS: Reactive oxygen species; RUNX2: Runt-related transcription factor 2; Sox9: SRY-Box 9; TGFβ: Transforming growth factor beta; TSPCs: Tendon stem progenitor cells; VEGF: Vascular endothelial growth factor; WJ-MSCs: Wharton’s jelly derived mesenchymal stem/stromal cells

Acknowledgements
The authors want to thank Dr. Alessandra Colombini and Dr. Paola de Luca for their help in literature revision.

Funding
None.

Availability of data and materials
Not applicable.

Authors’ contributions
MV and LDG for the literature search and analysis, and manuscript writing. VS and LDG for the final manuscript revision. MCD, PR, and CPO for manuscript writing. MV and LDG for the literature search and analysis, and manuscript writing. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Author details
1IRCCS Galeazzi Orthopaedic Institute, Via R. Galeazzi 4, 20161 Milan, Italy.
2Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.
3Department of Biomedical Science for Health, University of Milan, Milan, Italy.
4ESSWT Center, Rehabilitation Department, Humanitas Research Hospital, Rozzano, Milan, Italy.
5Department of Drug Sciences, University of Pavia, Pavia, Italy.

Received: 17 September 2016 Accepted: 28 November 2016
Published online: 16 December 2016

References
1. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11–5.
2. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marinì F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.
3. de Girolamo L, Lucarelli E, Alessandri G, Avanzini MA, Bernardo ME, Biagi E, Brini AT, D’Amico G, Fagiolini F, Ferrero I, Locatelli F, Maccario R, Manazzi M, Parolini O, Pessina A, Tome ML, Italian Mesenchymal Stem Cell Group. Mesenchymal stem/stromal cells: a new “cells as drugs” paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des. 2013;19(13):2459–73.
4. Bi Y, Hrichiou D, Kilms TM, Inkson CA, Embree MC, Sonoyama W, Li L, Leet AL, Seo BM, Zhang L, Shi S, Young MF. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med. 2007;13(10):1219–27.
5. Nakahara H, Goldberg VM, Caplan AI. Culture-expanded human periosteal-derived cells exhibit osteochondral potential in vivo. J Orthop Res. 1991;9(4):465–76.
6. Oszczka AM, Nöth U, Danielson KG, Tuan RS. Different osteochondral potential of clonal cell lines derived from adult human trabecular bone. Ann N Y Acad Sci. 2002;961:73–7.
7. Zük PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211–28.
8. De Bari C, Dell’Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001;44(8):1928–42.
9. Lu HH, Kofron MD, Al-Emin SF, Attawia MA, Laurencin CT. In vitro bone formation using muscle-derived cells: a new paradigm for bone tissue engineering using polymer-bone morphogenetic protein matrices. Biochem Biophys Res Commun. 2003;305(4):882–9.
10. Crisan M, Yap S, Castella i, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301–13.
11. Corselli M, Chen CW, Sun B, et al. The tunica adventitia of human arteries and veins as a source of mesenchymal stem/stromal cells. Stem Cells Dev. 2012;21:299–308.
12. Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol. 2008;36:733–41.
13. Murray IR, Corselli M, Petrogliano FA, Soo C, Pécaut B. Recent insights into the identity of mesenchymal stem cell: implications for orthopaedic applications. Bone Joint J. 2014;66-B(2):391–8.
14. Koh YG, Jo SB, Kwon OR, Suh DS, Lee SW, Park SH, Choi YJ. Mesenchymal stem cell injection improves symptoms of knee osteoarthritis. Arthroscopy. 2013;29(9):746–55.
15. Quarto R, Mastrogiacomo M, Cancedda R, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med. 2001;344:385–6.
16. Deng Z, Jin J, Zhao J, Xu H. Cartilage defect treatments: with or without cells? Mesenchymal stem cells or chondrocytes? Traditional or matrix-assisted? A systematic review and meta-analyses. Stem Cells Int. 2016;2016:201492.
17. de Girolamo L, Kon E, Filardo G, Marmotti AG, Soler F, Peretti GM, Vannini F, Madry H, Chubinskaya S. Regenerative approaches for the treatment of early OA. Knee Surg Sports Traumatol Arthrosoc. 2012;20(4):1826–35.
18. Gaspar D, Spanouderes K, Holladay C, Pandit A, Zeppolis D. Progress in cell-based therapies for tendon repair. Adv Drug Deliv Rev. 2015;84:240–56. doi:10.1016/j.addr.2014.11.023. Epub 2014 Dec 24.
19. Richardson SM, Kalamegam G, Pushparaj PN, Matta C, Memic A, Khademhosseini A, Mobasher R, Poletti FL, Hoyland JA, Mobasher A. Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration. Methods. 2016;9(4):469–80. doi:10.1016/j.ymeth.2015.09.015. Epub 2015 Sep 15.
20. Stanovici J, Le Nail LR, Brennan MA, Vidal L, Trichet V, Rosset P, Layrolle P. Bone regeneration strategies with bone marrow stromal cells in orthopaedic surgery. Curr Rev Translat Med. 2016;6(2):83–90. doi:10.1016/j.ctr.2016.04.006.
21. Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, Sentsis J, Sánchez A, García-Sancho J. Treatment of knee osteoarthrits with autologous mesenchymal stem cells: a pilot study. Transplantation. 2013;95(1):12135–41.
22. de Girolamo L, Bertolini G, Cervellin M, Sozzi G, Volpi P. Treatment of chondral defects of the knee with one step matrix-assisted technique enhanced by autologous concentrated bone marrow: in vitro characterisation of mesenchymal stem cells from iliac crest and subchondral bone. Injury. 2010;41:1172–7.
23. Hengartner NE, Fiedler J, Schrezenmeier H, Huber-Lang M, Brenner RE. Crucial role of IL-1beta and C3a in the in vitro-response of multipotent mesenchymal stromal cells to a inflammatory mediators of polycloty. PLoS ONE. 2015;10(1):e0161772.

24. Li D, Pan X, Zhao J, et al. Bone marrow mesenchymal stem cells suppress acute lung injury induced by lipopolysaccharide through inhibiting the Tlr2, 4/NF-κB pathway in rats with multi trauma. Shock. 2016;45(6):641–6.

25. Qi Y, Jiang D, Sindiriau A, et al. TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis immune full-thickness skin wounds. J Invest Derm. 2014;134(2):526–37.

26. Markov MS. Expanding use of pulsed electromagnetic field therapies. Electromagn Biol Med. 2007;26(3):267–74.

27. Chang K, Hong-Shong Chang W, Yu YH, Shih C. Pulsed electromagnetic field stimulation of bone marrow cells derived from ovariectomized rats affects osteoclast formation and local factor production. Bioelectromagnetics. 2004;25(2):134–41.

28. Li JK, Lin JC, Liu HC, Chang WH. Cytokine release from osteoblasts in response to different intensities of pulsed electromagnetic field stimulation. Electromagn Biol Med. 2007;26(3):153–65.

29. Patterson TE, Sakai Y, Grabiner MD, Ibiwoye M, Midura RJ, Zborowski M, Wolfman A. Exposure of murine cells to pulsed electromagnetic fields rapidly activates the mTOR signaling pathway. Bioelectromagnetics. 2006;27(7):535–44.

30. Markov MS. Myosin light chain phosphorylation modification depending on magnetic field strength. Theoretical Electromagn Biol. 2004;23:55–74.

31. Markov MS. Myosin phosphorylation—a plausible tool for studying biological windows. Ross Ady Memorial Lecture. In: Kostakis P, editor. Proceedings of Third International Workshop on Biological Effects of EMF. Kos, Greece: 2004. pp. 1–9.

32. Markov MS, Pilla AA. Ambient range sinusoidal and DC magnetic fields affect myosin phosphorylation in a cell-free preparation. In: Blank M, editor. Electricity and Magnetism in Biology and Medicine. San Francisco: San Francisco Press; 1993. p. 323–7.

33. Markov MS, Pilla AA. Static magnetic field modulation of myosin phosphorylation: calcium dependence in two enzyme preparations. Bioelectromagn Bioen. 1994;35:57–61.

34. Markov MS, Pilla AA. Modulation of cell-free myosin light chain phosphorylation with weak low frequency and static magnetic fields. In: Frey A, editor. On the Nature of Electromagnetic Field Interactions with Biological Systems. Austin: R.G. Landes Co.; 1994. p. 127–41.

35. Markov MS, Ryaby JT, et al. Extremely weak AC and DC magnetic field significantly affect myosin phosphorylation. In: Allen MJ, Cleary SF, Sowers AE, Shillady DD, editors. Charge and Field Effects in Biosystems-3. Boston: Birkhauser; 1992. p. 225–30.

36. Markov MS, Wang S, Pilla AA. Effects of low weak frequency sinusoidal and DC magnetic fields on myosin phosphorylation in a cell-free preparation. Bioelectromagn Bioen. 1993;30:119–25.

37. Markov MS, Muesham DJ, Pilla AA. Modulation of cell-free myosin phosphorylation with pulsed radio frequency electromagnetic fields. In: Allen MJ, Cleary SF, Sowers AE, editors. Charge and Field Effects in Biosystems 4. New Jersey: World Scientific; 1994. p. 274–88.

38. Varani K, De Mattei M, Vianello E, Corsi Romanelli MM, S ansone V. Low frequency pulsed electromagnetic fields enhance chondrogenesis of human adipose-derived stem cells in a chondrogenic microenvironment in vitro. J Appl Physiol (1985). 2013;114(5):647–55.

39. Esposito M, Lucarelli A, Costanzo C, Fiumarella A, Giannini A, Riccardi G, Ricci R. Differentiation of human umbilical cord-derived mesenchymal stem cells, WJ-MSCs, into chondrogenic cells in the presence of pulsed electromagnetic fields. In: Vivo. 2013;27(4):495–500.

40. Stanco D, Viganò M, Perucca Orfè C, Di Giancarillo A, Peretti GM, Lanfranchi L, di Girolamo L. Multidifferentiation potential of human mesenchymal stem cells from adipose tissue and hamstring tendons for musculoskeletal cell-based therapy. Regen Med. 2015;10(6):729–43. doi:10.2217/rme.14.92.

41. de Girolamo L, Stanco D, Galliera E, Viganò M, Colombari A, Setti S, Vianello E, Corsi Romanelli MM, Sansone V. Low frequency pulsed electromagnetic field affects proliferation, tissue-specific gene expression, and cytokines release of human tendon cells. Cell Biochem Biophys. 2013;66(3):697–708. doi:10.1007/s12013-013-9514-y.

42. de Girolamo L, Viganò M, Galliera E, Stanco D, Setti S, Marazzi MG, Thebat G, Corsi Romanelli MM, Sansone V. In vitro functional response of human tendon cells to different dosages of low-frequency pulsed electromagnetic field. Knee Surg Sports Traumatol Arthrosc. 2015;23(11):3443–53.

43. Di Agostino MC, Frairia R, Amelio E, Bosco V. Extracorporeal shockwaves as a plausible tool for studying cell biology and tissue regeneration therapy in orthopedic traumatology: a narrative review from basic research to clinical practice. J Biol Regul Homeost Agents. 2016;30(2):323–32.
60. Holfeld J, Tepeköylü C, Reissig C, Lobenwein D, Scheller B, Kirchmair E, Kozaryn R, Albrecht-Schogor K, Kräpf C, Zins K, Utschatat A, Zacharowski K, Grimm M, Kirchmair R, Paulus P. Toll-like receptor 3 signalling mediates angiogenic response upon shock wave treatment of ischaemic muscle. Cardiovasc. Res. 2016;109(2):331–43.
61. Wang F3, Yang KD, Chen RF, et al. Extracorporeal shock wave promotes growth and differentiation of bone marrow stromal cells towards osteoprogenitors associated with induction of TGF-β1. J Bone Joint Surg (Br). 2002;84:457–61.
62. Wang F3, Chen CJ, Chen MSC, et al. Superoxide mediates shock wave induction of ERK-dependent osteogenic transcription factor (C/EBF1) and mesenchymal cell differentiation toward osteoprogenitors. J Biolog Chem. 2002;277(13):10931–7.
63. Suhr F, Delhase Y, Burgartz G, Schmidt A, Pfannkuche K, Bloch W. Cell biological effects of mechanical stimulations generated by focused extracorporeal shock wave applications on cultured human bone marrow stromal cells. Stem Cell Res. 2013;11(2):951–64.
64. Aicher A, Heeschen C, Sasaki K, et al. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation. 2006;114(25):2823–30.
65. Mittermayr R, Antonic V, Hartinger J, et al. Extracorporeal shock wave therapy (ESWT) for wound healing: technology, mechanisms, and clinical efficacy. Wound Repair Regen. 2012;20(4):456–65.
66. Moosavi-Nejad SF, Hosseini SH, Satoh M, Takayama K. Shock wave induced cytoskeletal and morphological deformations in a human renal carcinoma cell line. Cancer Sci. 2006;97(4):296–304.
67. Berger M, Frairia R, Piacibello W, et al. Feasibility of cord blood stem cell manipulation with high-energy shock waves: an in vitro and in vivo study. Exp Hematol. 2005;33(11):1371–87.
68. Leone L, Raffa S, Vetrano M, Ranieri D, Malisan F, Scrofani C, Vulpiani MC, Ferretti A, Torrisi MR, Visco V. Extracorporeal shock wave treatment (ESWT) enhances the in vitro-induced differentiation of human tendon-derived stem/progenitor cells (hTSPCs). Oncotarget. 2016;7(6):6410–23.
69. de Girolamo L, Stanco D, Galliera E, Viganò M, Lovati AB, Marazza MG, Romeo P, Sansone V. Soft-focused extracorporeal shock waves increase the expression of tendon-specific markers and the release of anti-inflammatory cytokines in an adherent culture model of primary human tendon cells. Ultrasound Med Biol. 2014;40(6):1204–15.
70. Rinella L, Marano F, Berta L, Bosco O, Fracalvieri M, Fortunati N, Frairia R, Catalano MG. Extracorporeal shock waves modulate myofibroblast differentiation of adipose-derived stem cells. Wound Repair Regen. 2016;24(2):275–86.
71. Catalano MG, Marano F, Rinella L, de Girolamo L, Bosco O, Fortunati N, Berta L, Frairia R. Extracorporeal shockwaves (ESWs) enhance the osteogenic medium-induced differentiation of adipose-derived stem cells into osteoblast-like cells. J Tissue Eng Regen Med. 2014; doi: 10.1002/term.1922.
72. Schuh CM, Heher P, Welth AM, Banerjee A, Fuchs C, Gabriel C, Woltbank S, Mittermayr R, Redl H, Ränzlöf D, Teuschl AH. In vitro extracorporeal shock wave treatment enhances stemness and preserves multipotency of rat and human adipose-derived stem cells. Cytotherapy. 2014;16(12):1666–78.